Edgar Selzer1, Anja Grah2, Gregor Heiduschka3, Gabriela Kornek4, Dietmar Thurnher3. 1. Departments of Radiotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. edgar.selzer@meduniwien.ac.at. 2. Departments of Radiotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. 3. Otorhinolaryngology-Head and Neck Surgery, Medical University of Vienna, Vienna, Austria. 4. Internal Medicine I-Division of Clinical Oncology, Medical University of Vienna, Vienna, Austria.
Abstract
OBJECTIVES: The objective of this retrospective study was to clarify the potential prognostic significance of pre-therapeutic fibrinogen levels in head and neck squamous cell carcinoma (HNSCC) patients treated with curative intent by primary radiotherapy (RT) or with postoperative radiotherapy (PORT). PATIENTS AND METHODS: We retrospectively analyzed data from 347 patients with histologically confirmed locally advanced HNSCC. Analysis was conducted separately for the patient collective treated with PORT (N = 141; 85.1 % AJCC stage III/IV) and for patients treated with primary RT (N = 206; 97.1 % AJCC stage III/IV). Kaplan Meier analyses as well as univariate and multivariate survival analyses were performed to identify factors associated with overall survival (OS). RESULTS: The most relevant observation was that plasma fibrinogen levels were significantly associated with a reduction of overall survival rates. In the low-fibrinogen (below 411 mg/dL) postoperatively irradiated group, OS rates at 2 and 3 years were 86 and 83 %, and in the high-fibrinogen group 66 and 51 %, respectively. In the RT group with low fibrinogen levels, OS rates after 2 and 3 years were 74 and 53 %, and in the high-fibrinogen group 40 and 22 %, respectively. In multivariate analysis, elevated fibrinogen concentrations were associated with inferior OS in both the postoperatively (HR = 2.5; p = 0.001) as well as in the primarily irradiated (HR = 1.7; p = 0.003) group. CONCLUSIONS: We conclude from these results that elevated pre-therapeutic fibrinogen may serve as a biomarker associated with worsened prognosis in locally advanced head and neck cancer patients treated by either RT or surgery followed by adjuvant radiotherapy.
OBJECTIVES: The objective of this retrospective study was to clarify the potential prognostic significance of pre-therapeutic fibrinogen levels in head and neck squamous cell carcinoma (HNSCC) patients treated with curative intent by primary radiotherapy (RT) or with postoperative radiotherapy (PORT). PATIENTS AND METHODS: We retrospectively analyzed data from 347 patients with histologically confirmed locally advanced HNSCC. Analysis was conducted separately for the patient collective treated with PORT (N = 141; 85.1 % AJCC stage III/IV) and for patients treated with primary RT (N = 206; 97.1 % AJCC stage III/IV). Kaplan Meier analyses as well as univariate and multivariate survival analyses were performed to identify factors associated with overall survival (OS). RESULTS: The most relevant observation was that plasma fibrinogen levels were significantly associated with a reduction of overall survival rates. In the low-fibrinogen (below 411 mg/dL) postoperatively irradiated group, OS rates at 2 and 3 years were 86 and 83 %, and in the high-fibrinogen group 66 and 51 %, respectively. In the RT group with low fibrinogen levels, OS rates after 2 and 3 years were 74 and 53 %, and in the high-fibrinogen group 40 and 22 %, respectively. In multivariate analysis, elevated fibrinogen concentrations were associated with inferior OS in both the postoperatively (HR = 2.5; p = 0.001) as well as in the primarily irradiated (HR = 1.7; p = 0.003) group. CONCLUSIONS: We conclude from these results that elevated pre-therapeutic fibrinogen may serve as a biomarker associated with worsened prognosis in locally advanced head and neck cancerpatients treated by either RT or surgery followed by adjuvant radiotherapy.
Entities:
Keywords:
Biomarker; Fibrinogen; Head and neck cancer; Prognosis; Radiotherapy
Authors: Claudia Lill; Gabriela Kornek; Barbara Bachtiary; Edgar Selzer; Christian Schopper; Martina Mittlboeck; Martin Burian; Friedrich Wrba; Dietmar Thurnher Journal: Wien Klin Wochenschr Date: 2011-03-30 Impact factor: 1.704
Authors: V Seebacher; S Polterauer; C Grimm; H Husslein; H Leipold; K Hefler-Frischmuth; C Tempfer; A Reinthaller; L Hefler Journal: Br J Cancer Date: 2010-02-16 Impact factor: 7.640
Authors: Deirdre K Tobias; Akintunde O Akinkuolie; Paulette D Chandler; Patrick R Lawler; JoAnn E Manson; Julie E Buring; Paul M Ridker; Lu Wang; I-Min Lee; Samia Mora Journal: Am J Epidemiol Date: 2018-04-01 Impact factor: 4.897
Authors: Edyta Wolny-Rokicka; Katarzyna Brzeźniakiewicz-Janus; Jerzy Wydmański; Andrzej Tukiendorf; Agnieszka Zembroń-Łacny Journal: J Int Med Res Date: 2018-03-19 Impact factor: 1.671